Cargando…

Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study

Recurrent pharyngo-tonsillar infections caused by group A beta-hemolytic streptococci (GABHS) occur frequently in young children, and the treatment of these infections contributes substantially to the total current requirement for antibiotic prescribing. Our study goal was to assess through a retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregori, Giuseppe, Righi, Ornella, Risso, Paolo, Boiardi, Goffreda, Demuru, Giovanni, Ferzetti, Anna, Galli, Antonio, Ghisoni, Marco, Lenzini, Sonia, Marenghi, Claudio, Mura, Caterina, Sacchetti, Roberto, Suzzani, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725641/
https://www.ncbi.nlm.nih.gov/pubmed/26855579
http://dx.doi.org/10.2147/TCRM.S96134
_version_ 1782411659236605952
author Gregori, Giuseppe
Righi, Ornella
Risso, Paolo
Boiardi, Goffreda
Demuru, Giovanni
Ferzetti, Anna
Galli, Antonio
Ghisoni, Marco
Lenzini, Sonia
Marenghi, Claudio
Mura, Caterina
Sacchetti, Roberto
Suzzani, Lucia
author_facet Gregori, Giuseppe
Righi, Ornella
Risso, Paolo
Boiardi, Goffreda
Demuru, Giovanni
Ferzetti, Anna
Galli, Antonio
Ghisoni, Marco
Lenzini, Sonia
Marenghi, Claudio
Mura, Caterina
Sacchetti, Roberto
Suzzani, Lucia
author_sort Gregori, Giuseppe
collection PubMed
description Recurrent pharyngo-tonsillar infections caused by group A beta-hemolytic streptococci (GABHS) occur frequently in young children, and the treatment of these infections contributes substantially to the total current requirement for antibiotic prescribing. Our study goal was to assess through a retrospective observational analysis whether the administration of the oral probiotic, Streptococcus salivarius K12 (SsK12), could reduce the occurrence of GABHS pharyngo-tonsillar infections in children who had a recent history of recurrent episodes of these infections. Twelve primary care pediatricians identified, through their databases, a total of 130 children who had experienced recurrent GABHS pharyngo-tonsillar infections over a period of at least 6–12 months prior to their inclusion in the study. Of these children, 76 then undertook a 90-day program requiring once-a-day dosing with a commercially available (Bactoblis) lozenge containing SsK12. No probiotic supplement was given to the remaining 54 (control) children. Each subject was monitored for the occurrence of GABHS pharyngo-tonsillitis and also for acute otitis media, bronchitis, sinusitis, and bronchopneumonia for at least 12 months following their entry to the study. Even 9 months after the use of SsK12 had been stopped, the probability of new GABHS infections was significantly lower (P>0.001) when compared to the period before dosing commenced. When compared to the untreated children, those taking SsK12 appear to have had significantly fewer GABHS infections both during the 90-day period of prophylaxis and during the following 9 months (P<0.001). These observations are supportive of the use of probiotic SsK12 for the control of recurrent GABHS pharyngo-tonsillar infections in children, and as an associated benefit, the use of this probiotic could lead to reduced antibiotic consumption. Follow-up controlled prospective studies should now be initiated in order to further establish the efficacy of this newly emerging prophylactic strategy.
format Online
Article
Text
id pubmed-4725641
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47256412016-02-05 Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study Gregori, Giuseppe Righi, Ornella Risso, Paolo Boiardi, Goffreda Demuru, Giovanni Ferzetti, Anna Galli, Antonio Ghisoni, Marco Lenzini, Sonia Marenghi, Claudio Mura, Caterina Sacchetti, Roberto Suzzani, Lucia Ther Clin Risk Manag Original Research Recurrent pharyngo-tonsillar infections caused by group A beta-hemolytic streptococci (GABHS) occur frequently in young children, and the treatment of these infections contributes substantially to the total current requirement for antibiotic prescribing. Our study goal was to assess through a retrospective observational analysis whether the administration of the oral probiotic, Streptococcus salivarius K12 (SsK12), could reduce the occurrence of GABHS pharyngo-tonsillar infections in children who had a recent history of recurrent episodes of these infections. Twelve primary care pediatricians identified, through their databases, a total of 130 children who had experienced recurrent GABHS pharyngo-tonsillar infections over a period of at least 6–12 months prior to their inclusion in the study. Of these children, 76 then undertook a 90-day program requiring once-a-day dosing with a commercially available (Bactoblis) lozenge containing SsK12. No probiotic supplement was given to the remaining 54 (control) children. Each subject was monitored for the occurrence of GABHS pharyngo-tonsillitis and also for acute otitis media, bronchitis, sinusitis, and bronchopneumonia for at least 12 months following their entry to the study. Even 9 months after the use of SsK12 had been stopped, the probability of new GABHS infections was significantly lower (P>0.001) when compared to the period before dosing commenced. When compared to the untreated children, those taking SsK12 appear to have had significantly fewer GABHS infections both during the 90-day period of prophylaxis and during the following 9 months (P<0.001). These observations are supportive of the use of probiotic SsK12 for the control of recurrent GABHS pharyngo-tonsillar infections in children, and as an associated benefit, the use of this probiotic could lead to reduced antibiotic consumption. Follow-up controlled prospective studies should now be initiated in order to further establish the efficacy of this newly emerging prophylactic strategy. Dove Medical Press 2016-01-19 /pmc/articles/PMC4725641/ /pubmed/26855579 http://dx.doi.org/10.2147/TCRM.S96134 Text en © 2016 Gregori et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Gregori, Giuseppe
Righi, Ornella
Risso, Paolo
Boiardi, Goffreda
Demuru, Giovanni
Ferzetti, Anna
Galli, Antonio
Ghisoni, Marco
Lenzini, Sonia
Marenghi, Claudio
Mura, Caterina
Sacchetti, Roberto
Suzzani, Lucia
Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title_full Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title_fullStr Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title_full_unstemmed Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title_short Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study
title_sort reduction of group a beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic streptococcus salivarius k12: a retrospective observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725641/
https://www.ncbi.nlm.nih.gov/pubmed/26855579
http://dx.doi.org/10.2147/TCRM.S96134
work_keys_str_mv AT gregorigiuseppe reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT righiornella reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT rissopaolo reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT boiardigoffreda reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT demurugiovanni reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT ferzettianna reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT galliantonio reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT ghisonimarco reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT lenzinisonia reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT marenghiclaudio reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT muracaterina reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT sacchettiroberto reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy
AT suzzanilucia reductionofgroupabetahemolyticstreptococcuspharyngotonsillarinfectionsassociatedwithuseoftheoralprobioticstreptococcussalivariusk12aretrospectiveobservationalstudy